Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals (Q46356731)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18804512

Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals (English)

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18804512

visceral leishmaniasis

1 reference

based on heuristic

inferred from title

Leishmania infantum

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18804512

author name string

Naghmeh Khoshgoo

1

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18804512

Farnaz Zahedifard

2

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18804512

Hiva Azizi

3

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18804512

Yasaman Taslimi

4

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18804512

Maribel Jiménez Alonso

5

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18804512

language of work or name

0 references

publication date

18 September 2008

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18804512

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18804512

26

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18804512

46

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18804512

5822-5829

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18804512

Advances in leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Leishmania/HIV co-infections: epidemiology in Europe.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

The relationship between leishmaniasis and AIDS: the second 10 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Drug resistance in Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Drug resistance in Leishmania: similarities and differences to other organisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Clinical and parasitological evaluation of dogs naturally infected by Leishmania (Leishmania) chagasi submitted to treatment with meglumine antimoniate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Balancing immunity and pathology in visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Immunopathogenesis of infection with the visceralizing Leishmania species

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Leishmania vaccines: progress and problems.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Identification of a 30 kDa antigen from leishmania (L.) chagasi amastigotes implicated in protective cellular reponses in a murine model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Cysteine proteases of parasitic organisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Leishmania Cysteine Proteinases: From Gene to Subunit Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Cathepsin B-like cysteine proteinase-deficient mutants of Leishmania mexicana.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Functional analysis of cathepsin B-like cysteine proteases from Leishmania donovani complex. Evidence for the activation of latent transforming growth factor beta

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

T helper (h)1/Th2 and Leishmania: paradox rather than paradigm

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generati

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.08.065

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18804512

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18804512

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46356731&oldid=2107582025"